The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

Table 1

Risk groups in CHL: clinical criteria used by European Organisation for Research and Treatment of Cancer (EORTC) and German Hodgkin Lymphoma Study Group (GHSG) to define treatment groups. Abbreviations: ESR, erythrocyte sedimentation rate (mm/h); CS, clinical stage; MTR, mediastinum-to-thorax ratio.

	EORTC	GHSG
Risk factor (RF)	(1) Age ≥ 50 y	(1) Large mediastinal mass
	(2) B symptoms + ESR:	(2) Extranodal disease/massive spleen
	(a) No symptoms + ESR ≥ 50	(3) ESR
	(b) Symptoms + ESR ≥ 30	(a) >50 without B symptoms
	(3) >3 nodal areas	(b) >30 with B symptoms
	(4) MTR ≥ 0.35	(4) >3 involved nodal regions
Early stage without RFs	CS I-II	CS I-II
Early stage unfavourable/; intermediate stage	CS I-II with one RF	CS I or IIA with RF
		CS IIB with RF 3 or 4
Advanced stage	CS III-IV	CS IIB with RF 1 or 2
		CS III or IV